Savara has completed enrollment on a Phase 2 study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus lung infection (MRSA) in cystic fibrosis (CF) patients.

The purpose of this research study is to evaluate the effectiveness, safety, and pharmacokinetics of AeroVanc compared to placebo in subjects with CF and a chronic MRSA lung infection.

ENROLLMENT IS NOW COMPLETE.
THE MAP BELOW SHOWS THE PARTICIPATING STUDY CENTERS:

(click the markers on map for details)

Inhaled antibiotics are becoming the cornerstone of treatment in patients with cystic fibrosis and other chronic care patients who experience frequent lung infections, specifically Pseudomonas aeruginosa infections. Despite these advancements, there are currently no approved inhaled drugs or cures to treat methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis―a life-threatening infection known to shorten the lives of affected patients including children. Vancomycin administered intravenously is the antibiotic of choice for the treatment of MRSA-related bronchopneumonia in cystic fibrosis patients, however, this method does not achieve optimal penetration into the lungs and systemic toxicities limit its use in a chronic setting.

Savara Pharmaceuticals’ lead product candidate is AeroVanc™ (vancomycin hydrochloride inhalation powder), the first inhaled antibiotic being developed to address the growing population of MRSA-infected cystic fibrosis patients. By delivering vancomycin directly to the site of infection, AeroVanc has the ability to improve clinical efficacy and reduce adverse effects caused by broad-spectrum antibiotics.

Enrollment is now complete on the AeroVanc phase II trial that recruited cystic fibrosis (CF) patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection to determine the effectiveness, safety, and pharmacokinetics of a new investigational inhalable powder formulation of vancomycin (NCT01746095; http://clinicaltrials.gov). Research was supported by the Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, as well as the National Heart, Lung, and Blood Institute of the National Institutes of Health (award number R44HL112393). The content is solely the responsibility of Savara and may not represent the official views of either organization.